Histogen logo 300.jpg
Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
16 févr. 2021 08h00 HE | Histogen Inc
HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:...
Histogen logo 300.jpg
Histogen to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
06 janv. 2021 08h00 HE | Histogen Inc
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen logo 300.jpg
Histogen Announces Closing of $14.0 Million Upsized Public Offering
05 janv. 2021 16h05 HE | Histogen Inc
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen logo 300.jpg
Histogen Announces Pricing of $14.0 Million Upsized Public Offering
30 déc. 2020 22h25 HE | Histogen Inc
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen logo 300.jpg
Histogen Announces Filing an Investigational New Drug Application for HST-003
17 déc. 2020 08h00 HE | Histogen Inc
Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN...
Histogen logo 300.jpg
Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
01 déc. 2020 08h00 HE | Histogen Inc
HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Week 26 Final Study Results...
Histogen logo 300.jpg
Histogen Announces Closing of $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
16 nov. 2020 16h05 HE | Histogen Inc
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen logo 300.jpg
Histogen Announces $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12 nov. 2020 08h00 HE | Histogen Inc
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen logo 300.jpg
Histogen Reports Third Quarter 2020 Earnings and Provides Business Update
10 nov. 2020 16h05 HE | Histogen Inc
Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20 Received $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage...
Histogen logo 300.jpg
Histogen to Report Third Quarter 2020 Earnings on November 12, 2020
28 oct. 2020 16h30 HE | Histogen Inc
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...